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OBJECTIVE — To evaluate the discriminative power of the Diabetic Neuropathy Symptom
(DNS) and Diabetic Neuropathy Examination (DNE) scores for diagnosing diabetic polyneu-
ropathy (PNP), as well as their relation with cardiovascular autonomic function testing (cAFT)
and electro-diagnostic studies (EDS).
RESEARCH DESIGN AND METHODS — Three groups (matched for age and sex)
were selected: 24 diabetic patients with neuropathic foot ulcers (DU), 24 diabetic patients
without clinical neuropathy or ulcers (DC), and 21 control subjects without diabetes (C). In all
participants, the DNS and DNE scores were assessed and cAFT (heart rate variability [HRV],
baroreflex sensitivity [BRS]), and EDS were performed (Nerve Conduction Sum [NCS] score;
muscle fiber conduction velocity: fastest/slowest ratio [F/S ratio]).
RESULTS — Both the DNS and the DNE scores discriminated between the DU and DC groups
significantly (P  0.001). The DNE score even discriminated between DC and C (P  0.05).
Spearman’s correlation coefficients between both DNS and DNE scores and cAFT (HRV0.42
and 0.44; BRS 0.30 and 0.29, respectively) and EDS (NCS 0.51 and 0.62; F/S ratio 0.44
and 0.62, respectively) were high. Odds ratios were calculated for both DNS and DNE scores
with cAFT (HRV 4.4 and 5.7; BRS 20.7 and 14.2, respectively) and EDS (NCS 5.6 and 16.8; F/S
ratio 7.2 and 18.8, respectively).
CONCLUSIONS — The DNS and DNE scores are able to discriminate between patients with
and without PNP and are strongly related to cAFT and EDS. This further confirms the strength
of the DNS and DNE scores in diagnosing diabetic PNP in daily clinical practice.
Diabetes Care 26:697–701, 2003
One of the major risk factors for thedevelopment of diabetic foot com-plications is distal symmetric sen-
sorimotor polyneuropathy (PNP) (1,2).
For diagnosing PNP, no gold standard is
available. The San Antonio consensus
panel has recommended that at least one
measurement should be performed in five
different diagnostic categories (3). These
are symptom scoring, physical examina-
tion scoring, quantitative sensory testing
(QST), cardiovascular autonomic func-
tion testing (cAFT), and electro-diagnos-
tic studies (EDS).
Because none of the existing symp-
tom and physical examination scores for
diabetic PNP completely fulfilled meth-
odological criteria for diagnostic tests, the
Diabetic Neuropathy Symptom (DNS)
and Diabetic Neuropathy Examination
(DNE) scores were developed (4,5). (DNS
guidelines can be found in an online ap-
pendix at http://care.diabetesjournals.
org.) The construct validity of these scores
was studied in relation to Semmes Wein-
stein monofilaments and vibration per-
ception threshold testing (both forms of
QST) because of their predictive value to
the development of diabetic foot compli-
cations (6–9).
cAFT has an important prognostic
value for the prediction of diabetic foot
complications (8,10,11) and mortality
due to cardiovascular problems (12,13).
The prognostic value of EDS is less clear,
although EDS are supposed to be the most
sensitive diagnostic tool for diabetic PNP
(14). The relation between the DNS and
DNE scores and cAFT and EDS, respec-
tively, has not been studied.
The objective of this study was to as-
sess the discriminative power of the DNS
and DNE scores for diagnosing diabetic





All participants were recruited from the
Diabetes Outpatient Clinic (University
Hospital Groningen) and the Rehabilita-
tion Center Beatrixoord Haren after in-
formed consent was obtained. To study
the discriminative power of the DNS and
DNE scores, three groups of subjects were
studied. Patient records were consecu-
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
From the 1Rehabilitation Center, Tolbrug/Jeroen Bosch Hospital, Den Bosch, the Netherlands; the 2Northern
Center for Health Care Research, Groningen, the Netherlands; the 3Department of Internal Medicine,
University Hospital Groningen, Groningen, the Netherlands; the 4Department of Endocrinology, University
Hospital Groningen, Groningen, the Netherlands; the 5Department of Neurology, University Hospital Gro-
ningen, Groningen, the Netherlands; and the 6Department of Internal Medicine, Martini Hospital, Gro-
ningen, the Netherlands.
Address correspondence and reprint requests to Jan-Willem G. Meijer, MD, PhD, Rehabilitation Center
Tolbrug, PO Box 90153, 5200 ME Den Bosch, The Netherlands. E-mail: tolbrug@boschmedicentrum.nl.
Received for publication 3 June 2002 and accepted in revised form 26 November 2002.
Additional information for this article can be found in an online appendix at http://care.
diabetesjournals.org.
Abbreviations: BRS, baroreflex sensitivity; cAFT, cardiovascular autonomic function testing; DNE, Di-
abetic Neuropathy Examination; DNS, Diabetic Neuropathy Symptom; EDS, electro-diagnostic studies; F/S
ratio, fastest/slowest ratio; HRV, heart rate variability; MFCV, muscle fiber conduction velocity; NCS, Nerve
Conduction Sum; PNP, polyneuropathy; QST, quantitative sensory testing; RV, reference value.
A table elsewhere in this issue shows conventional and Syste`me International (SI) units and conversion
factors for many substances.
E p i d e m i o l o g y / H e a l t h S e r v i c e s / P s y c h o s o c i a l R e s e a r c h
O R I G I N A L A R T I C L E
DIABETES CARE, VOLUME 26, NUMBER 3, MARCH 2003 697
tively screened during our outpatient
clinics for patients with previous neuro-
pathic foot ulceration in whom peripheral
vascular disease was not considered to
have contributed to the foot ulcers. After
this screening, they were recruited in a
randomized order. The first group con-
sisted of 24 diabetic patients known to
have had neuropathic foot ulcers (DU
group). These ulcers were purely neuro-
pathic by origin, as confirmed by their
localization (plantar surface of the foot at
high-pressure points) and the absence of
peripheral arterial disease, as described
below. In the second group, 24 diabetic
patients without clinical neuropathy or
foot ulcers (DC group) were included. To
confirm this, the 10-g Semmes Weinstein
monofilament was tested on the plantar
surface of the hallux and central at the
heel. The ability to correctly sense the
monofilament in six trials on both loca-
tions was defined as normal, whereas the
inability to sense the monofilament cor-
rectly in one or more trials was defined as
disturbed. The third group consisted of
21 control subjects with normal glucose
tolerance (C group). All groups were
matched for sex and age (within 5 years),
and the diabetic groups were also
matched for duration and type of diabetes
(type 1/type 2 diabetes; type 1 diabetes
was considered on clinical grounds when
the onset of the disease was a ketoacidosis
or before the age of 40 years). Subjects
with a history of or clinically apparent
cardiac disease, with electrocardiographic
abnormalities, or who used -blockers or
calcium antagonists were excluded. Pe-
ripheral arterial disease was excluded by
normal ankle-arm indexes (0.90), toe-
arm indexes (0.70), and normal pleth-
ysmography (crest time 0.22 s) in all
groups. Normal glucose tolerance of the
control subjects was demonstrated by a
fasting capillary blood glucose 6.1
mmol/l and a blood glucose7.8 mmol/l
2 h after a 75-g oral glucose tolerance test.
Details of the clinical characteristics of
each group are given in Table 1.
Methods
The DNS and DNE scores (E.B.), cAFT
(J.L.), and EDS (J.v.d.H.) were performed
by different researchers who were blinded
to participant group. The researchers
were acting independently, and no infor-
mation about the results was exchanged
during the study. An overall Neuropathy
Sum score, according to the San Antonio
consensus, was composed.
DNS score
Both the DNS and DNE scores have been
described in detail elsewhere (4,5). In
short, the DNS score is a four-item vali-
dated symptom score, with high predic-
tive value to screen for PNP in diabetes
(4). Symptoms of unsteadiness in walk-
ing, neuropathic pain, paraesthesia, and
numbness are elicited. The presence of
one symptom is scored as 1 point; the
maximum score is 4 points. A score of 1 or
higher is defined as positive for PNP.
DNE score
The DNE score is a sensitive and validated
hierarchical scoring system (5). The score
contains two items concerning muscle
strength, one concerning reflexes, and
five concerning sensation (eight total
items). Each item is scored from 0 to 2 (0
is normal and 2 severely disturbed). The
maximum score is 16 points. A score of
3 points is defined as positive for PNP.
cAFT
Cardiovascular autonomic function was
assessed by analysis of heart rate variabil-
ity (HRV) and baroreflex sensitivity
(BRS). All participants were studied in the
morning. All measurements took place in
a quiet room with the temperature kept
constant at 22°C. Blood pressure was
monitored by a Finapres (Ohmeda 2300;
Ohmeda, Inglewood, CO) and heart rate
by an electrocardiogram monitor (Hewlett-
Packard 78351T; Hewlett-Packard, Palo
Alto, CA). After 30 min of supine rest, the
Finapres and electrocardiogram signals
were sampled at 100 Hz and stored on a
personal computer during 15 min. Off-
line, 300 s of each recording were ana-
lyzed by the CARSPAN program (IEC
ProGamma; IEC, Groningen, the Nether-
lands), as previously described (15,16).
After artifact correction and stationarity
check, discrete Fourier transformation of
systolic blood pressure and R-R interval
length measurement were performed.
HRV analysis was performed in accor-
dance with the guidelines of the Task
Force of the European Society of Cardiol-
ogy and the North American Society of
Pacing and Electrophysiology (17). The
total power frequency band of HRV was
defined as 0.02–0.40 Hz. Because no ref-
erence values (RVs) of HRV are available,
the median of the control group was used,
9.2 ln(ms2). BRS was determined by the
transfer function method and defined as
the mean modulus between systolic blood
pressure and HRV in the 0.07- to 0.14-Hz
frequency band with at least 0.5 coher-
ence, expressed in ms/mmHg (15,16,18).
A BRS 3 ms/mmHg has shown high
mortality rates in chronic heart failure and
after myocardial infarction, but in diabe-
tes, the prognostic value of the BRS is un-
known (19,20). Therefore, in this study, a
BRS3 ms/mmHg was considered indic-
ative for cardiovascular autonomic neu-
ropathy.
Electro-diagnostic testing (EDS)
Nerve conduction studies were per-
formed with standard surface stimulation
and recording techniques using an elec-
tromyograph type Nicolet Viking IIe and
IV with standard filter settings. All mea-
surements were performed after warming
in hot water (38°C) of forearm and lower
leg during at least 15 min. Peak-peak am-
plitudes were used. RVs from our own
laboratory were used, with abnormal val-
ues defined as 2 SD of normal mean
values.
Motor nerve conduction velocity
(RVs) were measured in the left median
(thenar) (RV 58.5  4.6 m/s [means 
SD]) and peroneal nerves (tibialis ante-
rior) (RV 57.8  7.1 m/s). Sensory nerve
Table 1—Patient characteristics
DU DC C
n 24 24 21
Mean age (years) 57.3  11.4 52.2  12.0 58.2  9.9
Sex (M/F) 14/10 13/11 10/11
Mean duration of diabetes (years) 16.9  12.0 13.1  9.8
Type 1/type 2 diabetes 5/19 8/16
Mean HbA1c (%) 8.3  1.1* 7.5  0.8
Data are means SD. C, control subjects; DC, diabetic patients without neuropathy; DU, diabetic patients
with neuropathic ulcer. *P  0.01.
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conduction velocities and amplitudes
were measured antidromically with ring
electrodes placed around the middle fin-
ger (median nerve) (RV 45.6  3.7 m/s)
and stimulation lateral of the Achilles ten-
don (sural nerve) (RV 47.4 3.6 m/s). An
overall Nerve Conduction Sum (NCS)
score was defined as the number of these
four nerves with an abnormal conduction
velocity, ranging from 0 (all normal) to 4
(all abnormal).
Invasive muscle fiber conduction ve-
locity (MFCV) measurements were per-
formed in the tibialis anterior muscle at
rest by means of needle electrodes
adapted from a previously described
method (21). In short, muscle fibers were
directly stimulated in the distal part of the
tibial anterior muscle by a small monopo-
lar needle electrode (cathode) using a sur-
face electrode as anode (filter settings 500
Hz–10 kHz, stimulation 0.2 ms, 1–2 mA).
The resulting muscle fiber action poten-
tials were detected at a known distance
(50–60 mm) by a small concentric needle
electrode. With this technique, action po-
tentials supposed to represent individual
muscle fibers were identified and the re-
sulting conduction velocities were calcu-
lated. As parameters, the mean invasive
MFCV and the fastest/slowest ratio (F/S
ratio) representing the scatter of conduc-
tion velocities were used and compared
with normative values from our own lab-
oratory (3.17  0.40; F/S ratio 1.47 
0.19, slowest 2.59 0.40, fastest 3.78
0.49).
Neuropathy Sum score
For this study, an overall score was com-
posed of the DNS score (symptom score),
DNE score (examination score), BRS
(cAFT), and NCS (EDS). Because Semmes
Weinstein monofilament testing was used
in patient selection, these data, represent-
ing QST as the fifth category of the San
Antonio consensus (3), were also avail-
able. These five tests together formed the
Neuropathy Sum score. For each abnor-
mal test result, 1 point was given; the
maximum score was 5 points.
Statistics
The statistical package SPSS-PC 10.0 was
used to compute the descriptive statistics:
ANOVA, 2 tests, independent samples t
test, Spearman’s correlation coefficient,
and odds ratios. Unless otherwise indi-
cated, means  SD are given. A P value
0.05 was considered statistically signif-
icant.
RESULTS — Table 1 shows the patient
characteristics. There were no significant
differences between the groups for mean
age (P 0.15) and sex (P 0.77) and, for
the DU and DC groups, duration (P 
0.23) and type of diabetes (P 0.33). The
mean HbA1c of the DC group was signif-
icantly lower (P  0.01) than that of the
DU group.
Results of DNS and DNE scores for
the three groups
For the DNS score, the scores (SD) of
the DU, DC, and C groups were 2.29 
1.23, 0.44  0.84, and 0.38  0.74, re-
spectively. Differences between DU and
both DC and C were significant, P 
0.001 in both cases, but not between DC
and C. For the DNE score, the scores
(SD) of the DU, DC, and C groups were
8.90  1.98, 1.46  2.02, and 0.43 
0.81, respectively. Significant differences
were found in all comparisons of the three
groups, between DU and both DC and C
groups, P 0.001 in both cases, and be-
tween DC and C (P  0.05).
There were no significant differences
for DNS and DNE scores for type 1 and
type 2 diabetic patients. There was a sig-
nificant correlation between the DNS and
DNE scores and HbA1c (0.35, P  0.01;
0.57, P  0.001, respectively), as well as
between the DNS and DNE scores and
duration of diabetes (0.41, P  0.01;
0.56, P 0.001, respectively). There was
no significant correlation between both
scores and subject age.
Results of the PNP tests
Table 2 shows the percentage of patients
in the three groups who scored abnormal
on the individual diagnostic tests and on
the Neuropathy Sum score. The DNS and
DNE scores correctly identified the DU
group in 96 and 100%, respectively, and
the healthy control subjects in 76 and
100%, respectively. Almost one-half
(47%) of the patients of the DC group and
40% of the C group scored at least 1 point
on the Neuropathy Sum score, which
means that they scored abnormal on at
least one diagnostic category of the San
Antonio consensus. Table 3 shows the
specified results on the Neuropathy Sum
score.
Relation of the DNS and DNE scores
with cAFT and EDS
In Table 4, the correlation between the
DNS and DNE scores and cAFT (BRS and
HRV) and EDS (NCS and invasive MFCV)
is shown. The odds ratios for these tests
are also shown.
CONCLUSIONS — This study shows
that the DNS and DNE scores are able to
differentiate between subjects with and
without neuropathy in diabetes. Previ-
ously, the construct validity of both scores
was studied in relation to Semmes Wein-
stein monofilaments and vibration per-
ception threshold testing (4,5)—two
quantitative sensory tests known to be
strong predictors for the development of
Table 2—Results of the tests for PNP for the three groups
DU DC C
n 24 24 21
DNS (% 1 point  abnormal) 96% 26% 24%
DNE (% 3 points  abnormal) 100% 13% 0%
NCS (% 1 point  abnormal) 85% 32% 15%
F/S ratio (% 1.9  abnormal) 91% 33% 10%
BRS (% 3 ms/mmHG) 52% 0% 11%
HRVtp (% median) 95% 57% 50%
Neuropathy Sum score (% 1 point) 100% 47% 40%
Data are means SD. C, control subjects; DC, diabetic patients without neuropathy; DU, diabetic patients
with neuropathic ulcer. HRVtp, total power of HRV (abnormal defined as less than the median of the control
group).
Table 3—The number of patients with nor-
mal (0) or abnormal scores (1–5) on the Neu-
ropathy Sum (NS) score for the three groups
NS score 0 1 2 3 4 5
DU (22) 1 12 6 3
DC (23) 12 7 3 1
C (20) 12 6 2
C, control subjects; DC, diabetic patients without
neuropathy; DU, diabetic patients with neuropathic
ulcer.
Meijer and Associates
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diabetic foot complications. In this re-
port, the DNS and DNE scores are further
validated with the EDS and cAFT. There is
a strong relation between the DNS and
DNE scores and EDS in both nerve and
muscle fiber conduction studies. Further-
more, the relation of the DNS and DNE
scores with cAFT is significant, although
this is stronger for HRV than for BRS for
both scores. These results further confirm
the strength of the DNS and DNE scores
in diagnosing diabetic PNP.
HRV and BRS are advanced measures
that are able to detect early abnormalities
in cAFT (10–13). The relation of HRV
with the parameters for PNP (DNS and
DNE scores, NCS, and F/S ratio of MFCV)
is stronger than for BRS. While HRV mea-
sures the efferent part of the baroreflex
arc, i.e., vagal and sympathetic nerve–
mediated modulation of heart rate, BRS
measures the relation between input
(blood pressure sensed at the carotid ar-
teries and aorta baroreceptors) and the
output (modulations of heart rate, myo-
cardial contractility, and peripheral arte-
rial resistance) of the baroreflex. Thus, the
differences in HRV and BRS in relation to
diabetic PNP may be due to the fact that
BRS assesses different aspects of cardio-
vascular reflex function than HRV. Inter-
estingly, it has also been proposed that
PNP and cAFT are distinct entities with a
different pathogenesis (22), thereby ex-
plaining the previously noticed variable
relation between cAFT and PNP.
The odds ratios for the DNS and DNE
scores with NCS, MFCV (F/S ratio), HRV,
and BRS are high, which means that the
DNS and DNE scores are able to predict
the results of these other diagnostic tests.
By assessing the DNS and DNE scores at
the outpatient clinic, a good indication is
given for performing these more labori-
ous and expensive and less patient-
friendly laboratory tests. However, in our
opinion, the necessity of complementary
performance of cAFT and EDS with the
DNS and DNE scores, as proposed in the
San Antonio consensus, is debatable in
clinical practice. No specific therapeutic
interventions are available for neuropathy
except strict glycemic control, symptom-
atic treatment of, for example, neuro-
pathic pain, prevention, and instruction.
For screening, prevention, and instruc-
tion, the performance of the DNS and
DNE scores, eventually in combination
with QST, may be sufficient.
As expected, performance of these
various tests for diabetic PNP shows a
high number of abnormalities among the
group of patients with neuropathic ulcers.
Although the percentage with abnormal
BRS is rather low compared with the per-
centages of the other tests, these patients
are expected to have a very poor progno-
sis due to their high risk of cardiovascular
complications (19,20). In their treatment,
hospitalization, and rehabilitation pro-
gram, this should be taken into account.
Strikingly, 48% of this group with obvi-
ous neuropathy has a BRS3 ms/mmHg.
This supports the hypothesis that cAFT
might develop differently from PNP as an
independent complication of diabetes.
In both the diabetic group without
neuropathy and the control group, abnor-
mal test results were found for most tests.
This might be caused by lack of specificity
of the tests, as shown in the control group,
although it also shows that after careful
and sensitive screening, more abnormali-
ties can be found (also in diabetic patients
not known to have neuropathy), as ex-
pected after checking the records. The re-
sults of the DNS and Neuropathy Sum
scores are most striking. In our previous
DNS score validation, we chose a cutoff
value of1 to define a sensitive measure
for diabetic PNP. Our present values
show that almost one-quarter of our con-
trol group scores were abnormal. The
same problem will exist for other symp-
tom scores, such as for the Neuropathy
Symptom Score (NSS) (14,23), because
these scores also score these four items of
the DNS score. The Neuropathy Sum
score, based on the five diagnostic catego-
ries as advised by the San Antonio con-
sensus (3), also shows high percentages of
participants, even in the control group,
with abnormal test results. Therefore, one
should consider the risk of overdiagnosis
by using all five the diagnostic categories
of the San Antonio consensus. Further re-
search should be done to characterize an
optimal set of diagnostic categories for di-
abetic PNP.
In conclusion, this report shows that
the DNS and DNE scores allow discrimi-
nation between patients with and without
diabetic PNP. Both scores are strongly re-
lated to EDS and cAFT. These results, to-
gether with the previously published
results of the validation of both scores,
further confirm the strength of the DNS
and DNE scores in diagnosing diabetic
PNP in clinical practice.
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